Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System
Aurora Spine (OTCQB: ASAPF) announced the publication of a biomechanical study in Neurospine journal, demonstrating the superior performance of their SiLO TFX™ MIS Sacroiliac Joint Fixation System compared to traditional techniques.
The study revealed that the posterior interposition technique used by SiLO TFX™ achieved a 42% ± 8% reduction in joint motion, significantly outperforming the 14% ± 4% reduction observed with conventional posterolateral transosseous techniques. The system maintained stable bone-implant interface across all specimens, while traditional methods showed migration in 20%-50% of cases.
Key advantages of the SiLO TFX™ system include:
- Less bone volume removal
- Larger surface area for fusion
- Enhanced stability through transfixing design
- Minimally invasive approach
Aurora Spine (OTCQB: ASAPF) ha annunciato la pubblicazione di uno studio biomeccanico nella rivista Neurospine, dimostrando le prestazioni superiori del loro SiLO TFX™ MIS Sacroiliac Joint Fixation System rispetto alle tecniche tradizionali.
Lo studio ha rivelato che la tecnica di interposizione posteriore utilizzata da SiLO TFX™ ha ottenuto una riduzione del 42% ± 8% nel movimento articolare, superando significativamente la riduzione del 14% ± 4% osservata con le tecniche tradizionali posterolaterali transossee. Il sistema ha mantenuto un'interfaccia osso-impianto stabile in tutti i campioni, mentre i metodi tradizionali hanno mostrato migrazione nel 20%-50% dei casi.
I principali vantaggi del sistema SiLO TFX™ includono:
- Minore rimozione di volume osseo
- Maggiore superficie per la fusione
- Stabilità migliorata grazie al design trasfixante
- Approccio minimamente invasivo
Aurora Spine (OTCQB: ASAPF) anunció la publicación de un estudio biomecánico en la revista Neurospine, demostrando el rendimiento superior de su SiLO TFX™ MIS Sacroiliac Joint Fixation System en comparación con técnicas tradicionales.
El estudio reveló que la técnica de interposición posterior utilizada por SiLO TFX™ logró una reducción del 42% ± 8% en el movimiento articular, superando significativamente la reducción del 14% ± 4% observada con técnicas transóseas posterolaterales convencionales. El sistema mantuvo una interfaz óseo-implante estable en todos los especímenes, mientras que los métodos tradicionales mostraron migración en el 20%-50% de los casos.
Las principales ventajas del sistema SiLO TFX™ incluyen:
- Menor volumen óseo removido
- Mayor área de superficie para fusión
- Estabilidad mejorada a través de un diseño de transfixión
- Enfoque mínimamente invasivo
오로라 스파인 (OTCQB: ASAPF)는 신경척추 저널에 생체역학 연구의 발표를 알리며, 전통적인 기술에 비해 SiLO TFX™ MIS 천장관절 고정 시스템의 우수한 성능을 입증했습니다.
연구 결과, SiLO TFX™에서 사용된 후방 중재 기술이 관절 움직임에서 42% ± 8%의 감소를 달성하여, 기존의 후외측 관통 기술에서 관찰된 14% ± 4%의 감소를 크게 초과했습니다. 이 시스템은 모든 샘플에서 안정적인 뼈-임플란트 인터페이스를 유지했으며, 전통적인 방법은 20%-50%의 사례에서 이동을 보였습니다.
SiLO TFX™ 시스템의 주요 장점은 다음과 같습니다:
- 뼈 부피 제거 감소
- 융합을 위한 더 큰 표면적
- 관통 설계를 통한 향상된 안정성
- 최소 침습적 접근법
Aurora Spine (OTCQB: ASAPF) a annoncé la publication d'une étude biomécanique dans la revue Neurospine, démontrant la performance supérieure de leur SiLO TFX™ MIS Système de Fixation de l'Articulation Sacro-Iliaque par rapport aux techniques traditionnelles.
L'étude a révélé que la technique d'interposition postérieure utilisée par SiLO TFX™ a obtenu une réduction de 42% ± 8% du mouvement articulaire, surpassant de manière significative la réduction de 14% ± 4% observée avec les techniques transosséennes posterolatérales conventionnelles. Le système a maintenu une interface os-implant stable sur tous les échantillons, tandis que les méthodes traditionnelles ont montré une migration dans 20%-50% des cas.
Les principaux avantages du système SiLO TFX™ incluent:
- Moins d'élimination de volume osseux
- Surface plus grande pour la fusion
- Stabilité améliorée grâce à un design de transfixion
- Approche minimement invasive
Aurora Spine (OTCQB: ASAPF) gab die Veröffentlichung einer biomechanischen Studie in der Zeitschrift Neurospine bekannt, die die überlegene Leistung ihres SiLO TFX™ MIS Sakroiliakalgelenk-Fixationssystems im Vergleich zu traditionellen Techniken demonstriert.
Die Studie zeigte, dass die von SiLO TFX™ verwendete hintere Interpositionstechnik eine Reduktion von 42% ± 8% der Gelenkbewegung erreichte, was die 14% ± 4% Reduktion, die bei herkömmlichen posterolateralen transossären Techniken beobachtet wurde, erheblich übertraf. Das System hielt die stabile Knochen-Implantat-Schnittstelle über alle Proben hinweg, während traditionelle Methoden in 20%-50% der Fälle Migration zeigten.
Die wichtigsten Vorteile des SiLO TFX™-Systems sind:
- Weniger Knochenvolumenentfernung
- Größere Oberfläche für die Fusion
- Verbesserte Stabilität durch durchdringendes Design
- Minimalinvasiver Ansatz
- Clinical study demonstrates superior biomechanical performance over traditional techniques
- 42% reduction in joint motion vs 14% with traditional methods
- Zero implant migration vs 20-50% migration in traditional methods
- System preserves more bone volume and provides larger fusion surface area
- None.
CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in the journal Neurospine. The study evaluates the biomechanical performance of Aurora Spine's SiLO TFX™ MIS Sacroiliac Joint Fixation System compared to traditional posterolateral transosseous techniques.
The SiLO TFX™ system is a minimally invasive solution designed for sacroiliac joint fusion, addressing conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw, and associated instrumentation, engineered to transfix the sacrum and ilium, thereby providing stability conducive to bony fusion. The SiLO TFX™ system is designed in accordance with the AO Principles of Fusion—providing mechanical stability, preserving vascular supply, minimizing soft tissue disruption, and promoting an optimal environment for bone healing by proper decortication and the use of bone graft.
The study's findings indicate that the posterior interposition technique, as employed by the SiLO TFX system, removes less bone volume and offers a larger surface area for bony fusion compared to the posterolateral transosseous technique. Specifically, the posterior interposition technique resulted in a
Trent Northcutt, President and CEO of Aurora Spine, expressed satisfaction with the outcomes of the biomechanical study conducted. "The study demonstrated the superior performance of the SiLO TFX system in sacroiliac joint fusion. These findings align with Aurora Spine’s commitment to developing innovative, minimally invasive solutions that optimize patient outcomes and establish new standards in sacroiliac joint care."
Dr. Michael Stoffman, University at Buffalo Neurosurgery, Buffalo, NY, one of the study's authors, stated: "The posterior interposition technique demonstrated significant advantages in reducing joint motion and preserving bone integrity. This approach offers a promising alternative to traditional methods, potentially leading to improved patient recovery and long-term success."
Dr. Steven M. Falowski from Neurosurgical Associates of Lancaster, Lancaster, PA added: "Our research indicates that the SiLO TFX system provides enhanced stability and durability in sacroiliac joint fixation. The reduced bone removal and increased fusion surface area are critical factors in achieving successful surgical outcomes."
Dr. Jason E. Pope, Evolve Restorative Center, Santa Rosa, CA, remarked: "The study's outcomes highlight the biomechanics of the posterior interposition technique in sacroiliac joint fusion. The data suggests it is a viable treatment option for those suffering from sacroiliac joint disease and future clinical data on safety and efficacy is ongoing."
Aurora Spine remains dedicated to advancing spinal health through continuous innovation and collaboration with leading medical professionals. The publication of this study reinforces the company's position at the forefront of spinal implant technology.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
For more information about Aurora Spine and the SiLO TFX MIS Sacroiliac Joint Fixation System, please visit www.aurora-spine.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the Company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release, and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
FAQ
What are the key performance metrics of Aurora Spine's SiLO TFX system compared to traditional methods?
How does the ASAPF's SiLO TFX system preserve bone integrity during sacroiliac joint fusion?
What are the main components of Aurora Spine's SiLO TFX sacroiliac joint fusion system?
What clinical conditions does the ASAPF's SiLO TFX system address?
